Click Here: To read our COVID-19 Patient Guidelines before your visit.

  • In response to the Covid-19 pandemic, our office is following guidelines from New Jersey Department of Health.
  • For everyone's well-being, all patients and visitor must wear a face covering at all times in our office. We ask that no visitors accompany patients unless special assistance is required and then please limit to one visitor. Also please practice social distancing.
  • When arriving at our office, patients (and if necessary, visitor) will have to answer health screening questions and have their temperature checked. Anyone who is sick or had exposure to Covid will be asked to reschedule their appointment.
  • Please be assured that we are taking all precautions possible to protect our patients and staff. This includes frequent disinfection of the waiting room, patient exam rooms between patients and installing partitions between patient and staff during check-in and check-out.

Princeton Hypertension-Nephrology Associates

Nationally Designated Hypertension Practice Centers in the US by the American Society of Hypertension

Michael Ruddy MD

Michael C. Ruddy, M.D., F.A.C.P

Undergraduate College: Providence College, Providence, RI

Four-year National Institutes of Health full scholarship for Honors Science Program

Medical School: Rutgers-New Jersey Medical School, Newark, NJ

Medical Residency: Rutgers-Robert Wood Johnson Medical School Affiliated Hospitals, Piscataway, NJ

Chief Medical Resident: Rutgers-Robert Wood Johnson Medical School Affiliated Hospitals

Renal Fellowship: New York-Presbyterian Weill Cornell Medical Center, New York, NY

Fellow, American College of Physicians

Board Certified in Internal Medicine and Nephrology by the American Board of Internal Medicine

Fellow of the American Society of Hypertension

Current Academic Positions

  • Clinical Professor of Medicine and Adjunct Associate Professor of Pharmacology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ
  • Chief Section of Nephrology –University Medical Center of Princeton at Plainsboro, NJ

Honors and Awards

  • Top Doctor New York Metro Area Castle-Connolly Medical, Ltd., 2001 – 2015
  • Alpha Omega Alpha - Inducted as a faculty member; Rutgers- Robert Wood Johnson Medical School – 2006
  • Top Doctor New Jersey Monthly - November, 2006
  • Volunteer Faculty Award – Rutgers-Robert Wood Johnson Medical School – 2005
  • Research Mentor of the Year- medical housestaff of the RWJ Medical School Residency program - 2004.
  • Co-Teacher of the Year, Medical Housestaff, RWJMS Program -2003.
  • America’s Top Physicians – Consumers’ Research Council of America, 2003-2013
  • Cited among the first 200 physicians in the US to receive designation as a Specialist in Clinical Hypertension by the American Society of Hypertension, 1999.
  • 31st Annual Harold J Jeghers Lecturer, Rutgers-New Jersey Medical School, 1999.
  • President, New Jersey Society of Hypertension, 1992-93


Ruddy MC. Water metabolism and disorders of plasma sodium and potassium concentration. In: Manual for Clinical Nephrology. Stenzel KH, Cheigh J, eds.The Hague:Martinus Nijoff Publ., 30-67, 1981.

Ruddy MC, Atlas SA, Salerno F. Hypertension associated with a renin-producing adenocarcinoma of the pancreas. New England Journal of Medicine. 307:993-997, 1982.

Ruddy MC. Labile Hypertension. Journal of the American Medical Association. 248:1642, 1982.

Ruddy MC, Rubin AL, Novogrodsky A, Stenzel KH. Decreased macrophage mediated suppression of lymphocyte activation in chronic renal failure. American Journal of Medicine 75:571-579, 1983.

Masur H, Franciolo P, Ruddy MC, Murray H. Vancomycin serum levels and toxicity in chronic hemodialysis patients with staphylococcus aureus bacteremia. Clinical Nephrology 20:85-88, 1983.

Kostis J, Ruddy MC. The use of pindolol in the treatment of hypertension. Primary Cardiology 9:53-76, 1983.

Atlas SA, Hesson TE, Sealey JE, Laragh JH, Ruddy MC, Aurell M. Characterization of inactive renin ("prorenin") from renin-secreting tumors of non-renal origin: similarity to inactive renin from kidney and normal plasma. Journal of Clinical Investigation. 73:437-447, 1984.

Ruddy MC, Barone J. Pharmacology of Renal Hypertension. In: Hypertension and the Kidney. Cheigh J, Stenzel KH, eds. The Hague: Martinus Nijoff Publ., 1986.

Ruddy MC. Selection of Initial Therapy in Essential Hypertension. In: Pharmacological Treatment of Cardiovascular Disease edited by EA DeFelice, JB Kostis. Medical Examination Publishing Company 6:93-100, 1986.

Sherman RA, Ruddy MC. Suppression of Aldosterone Production by low-dose Heparin. American Journal of Nephrology 6:165-8, 1986.

Ruddy MC, Bialy GB. Angiotensin Converting Enzyme Inhibitors in Combination Therapy. In: Angiotensin Converting Enzyme Inhibitors. ed JB Kostis, E De Felice, Alan R. Liss, Inc. New York, NY, 1987.

Ruddy MC, Amorosa JK. Renovascular Hypertension: The Diagnostic Role of Radiologic Techniques. Applied Imaging. Volume 6 No. 1:1-5, 1988.

Ruddy MC, Bialy GB, Malka ES, Lacy CR, Kostis JB. The Relationship of Plasma Renin Activity to Clinic and Ambulatory Blood Pressure in Elderly People with Isolated Systolic Hypertension. Journal of Hypertension 1988, 6 (suppl 4):S412-S415.

Bialy GB, Ruddy MC, Malka ES, Kamalakannan N. Comparison of Office, Home and 24-Hour Ambulatory Blood Pressures in Borderline and Mild Hypertension. Angiology 752-760, 1988.

Ruddy MC, Bialy GB, Kostis JB. Intrinsic Sympathomimetic Activity Counteracts Beta Blocker Inhibition of Renin Activation. Angiology 40:45-50, 1989.

Ruddy MC. et. al. The effects of benazepril, a new angiotensin- converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study. Clinical Pharmacology and Therapeutics 1991:49(3):322-329.

Ruddy MC, Arora A, Malka E, Bialy GB. Blood Pressure Variability and Urinary Electrolyte Excretion in Normotensive Adults. American Journal of Hypertension 1993:6:480-486.

Carson JL, Ruddy MC, Brolin, RE, Duff A, Cody RP. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Archives of Internal Medicine 1994. Vol 154, P 193-200.

Ruddy MC, Kostis JB, Frishman W. Drugs that Inhibit the Renin Angiotensin System. In Cardiovascular Pharmacotherapeutics. Frishman W, Sonnenblick E, eds. McGraw Hill, New York,1997.

Ruddy MC. The INSIGHT and NORDIL Trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection? Current Hypertension Reports 2001; 3:289-296.

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rhode R and Raz I, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.

Ruddy MC. Angiotensin II Receptor Blockade in Diabetic Nephropathy. Editiorial.Am J Hypertension, 2002; 15:468-471.

Ferrario C, Smith RD, Brosnihan K, Chappell M, Campese V, Vesterqvisy O, Liao W, Ruddy M, Grim C. Effects of Omapatrilat on the renin angiotensin system in salt sensitive hypertension. Am J Hypertension 2002;15:557-564.

Ruddy MC, Kostis JB. Angiotensin II Receptor Antagonists. In Hypertension: A Companion to Brenner & Rector’s The Kidney. 2nd edition, Oparil S, Weber M, eds. W.B. Saunders Company, Philadelphia, 2005.

Ruddy MC. Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition. Postgraduate Medicine 2010;122:203-212.

Ruddy MC. New Hypertension Management Guideline: Internal Medicine World Report, May 2014.